<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05091749</url>
  </required_header>
  <id_info>
    <org_study_id>2021-16</org_study_id>
    <secondary_id>2021-A02200-41</secondary_id>
    <nct_id>NCT05091749</nct_id>
  </id_info>
  <brief_title>Detection of Significant Coronary Artery Disease by Promising Biomarker: A2A Adenosine Receptor (A2AR) Assays</brief_title>
  <acronym>ADOCAD</acronym>
  <official_title>Detection of Significant Coronary Artery Disease by Promising Biomarker: A2A Adenosine Receptor (A2AR) Assays</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transversal, national, multi-center study with progressive recruitment designed to assess the&#xD;
      diagnostic accuracy of A2AR expression for the identification of significant obstructive CAD&#xD;
      (FFR&lt;0.8) of patients suspected of CCS compared to the gold standard.&#xD;
&#xD;
        1. To assess the diagnostic accuracy of the A2AR profile (i.e. KD/EC50) for identifying&#xD;
           myocardial ischemia in patients with suspected CCS compared to the gold standard&#xD;
           inducible myocardial ischemia.&#xD;
&#xD;
        2. To determine the best threshold value for A2AR expression for identifying significant&#xD;
           obstructive CAD (FFR&lt;0,8) in patients with CCS, and to estimate the diagnostic&#xD;
           performances associated with the identified threshold&#xD;
&#xD;
        3. To determine the best threshold value for A2AR profile (i.e. KD/EC50) for identifying&#xD;
           myocardial ischemia (See annex 2) in patients with CCS and to estimate the diagnostic&#xD;
           performances associated with the identified threshold.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A 2AR measure</measure>
    <time_frame>24 MONTHS</time_frame>
    <description>blood sample</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Chronic Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>chronic coronary syndromes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>troponin measurement</description>
    <arm_group_label>chronic coronary syndromes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman aged ≥18 and &lt;90 years old;&#xD;
&#xD;
          -  Must not be of child-bearing potential (≥1 year post-menopausal, contraceptive, or&#xD;
             surgically sterile);&#xD;
&#xD;
          -  Symptoms suggestive of CCS and intermediate PTP (15-85%) according to the Diamond&#xD;
             classification (2);&#xD;
&#xD;
          -  Undergone at least one stress imaging test (annex 3) or an abnormal coronary Computed&#xD;
             Tomography Angiography (CTA) with the recommendation to perform ICA with FFR in all&#xD;
             intermediate lesions;&#xD;
&#xD;
          -  Non-contributive ECG (resting 18-lead);&#xD;
&#xD;
          -  Normal echocardiography with left ventricular ejection fraction (LVEF) &gt;50%;&#xD;
&#xD;
          -  Cardiac troponin level &lt;99th percentile;&#xD;
&#xD;
          -  Intended for an invasive strategy for CCS;&#xD;
&#xD;
          -  Affiliated to or beneficiary of, a social security system;&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Persons referred in articles L.1121-5 to L.1121-8 and L.1122-2 of the Public Health Code:&#xD;
&#xD;
          -  Pregnant, parturient or breastfeeding woman&#xD;
&#xD;
          -  Person deprived of liberty for judicial or administrative decision&#xD;
&#xD;
          -  Person under psychiatric care&#xD;
&#xD;
          -  Minor person (non-emancipated)&#xD;
&#xD;
               -  History of CAD or known CAD&#xD;
&#xD;
               -  Suspected acute coronary syndrome (ACS: annex 4)&#xD;
&#xD;
               -  Inability to undergo adenosine testing&#xD;
&#xD;
               -  Allergy to iodinated contrast media&#xD;
&#xD;
               -  Bleeding diathesis&#xD;
&#xD;
               -  Known significant bleeding risk according to physician judgment&#xD;
&#xD;
               -  Severe hepatic failure (ASAT, ALAT&gt;3ULN)&#xD;
&#xD;
               -  Ischemic stroke within 1 month or a history of hemorrhagic stroke&#xD;
&#xD;
               -  Bradycardia&#xD;
&#xD;
               -  Platelet count &lt;100 G/L&#xD;
&#xD;
               -  Hemoglobin &lt;10g/dl&#xD;
&#xD;
               -  Major surgery or trauma within 10 days&#xD;
&#xD;
               -  Life expectancy &lt;1 year&#xD;
&#xD;
               -  Pre-test Probability &lt;15% or &gt;85%&#xD;
&#xD;
               -  History and clinical examination suggesting non-cardiac chest pain&#xD;
&#xD;
               -  Contraindication to coronary angiography&#xD;
&#xD;
               -  Thyroid disorder&#xD;
&#xD;
               -  Refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CREMIEUX François</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PAGANELLI FRANCK</last_name>
    <phone>04 96 88 83</phone>
    <email>franck.paganelli@ap-hm.fr</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

